BDNF
BDNF 詳細
| 英語名 | Brain-derived neurotrophic factor | 市販薬剤の数 | 0 |
| 治験薬の数 | 8 | ターゲットの別称 | Brain-Derived Neurotrophic Factor，Abrineurin，ANON2，Brain Derived Neurotrophic Factor，BULN2，ProBDNF，Neurotrophin |
| 研究＆開発段階 | Phase 3 Clinical | ||
| 英語名 | Brain-derived neurotrophic factor |
| ターゲットの別称 | Brain-Derived Neurotrophic Factor，Abrineurin，ANON2，Brain Derived Neurotrophic Factor，BULN2，ProBDNF，Neurotrophin |
| 市販薬剤の数 | 0 |
| 治験薬の数 | 8 |
| 研究＆開発段階 | Phase 3 Clinical |
BDNF 製品リスト
- 属性
Protein (4)
- 製品ライブラリ
オンライン (4)
- 種
Human (4)
- タグ
Tag Free (4)
- マーカー
Unconjugated (4)
| 製品番号 | 種 | 発現システム | 製品説明 | タンパク質の構造 | 純度 | 特性 |
|---|---|---|---|---|---|---|
HOT GMP-BDFH15 |  Human | E. coli | GMP Human BDNF Protein (E. coli) |  |  | |
| Human | E. coli | Human BDNF / Abrineurin Protein (E. coli), premium grade |  | |  | |
| Human | E. coli | Human BDNF / Abrineurin Protein (E. coli), Research Grade |  | | ||
| Human | HEK293 | Human BDNF / Abrineurin Protein (HEK293), premium grade |  | |  |
総数量4
- 1
BDNFバックグランド
Brain-derived neurotrophic factor (BDNF) along with nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are members of the neurotrophin family of trophic factors. The neurotrophins play essential roles in the development, survival, and function of a wide range of neurons in both the peripheral and central nervous systems. The neurotrophins interact with two cell surface receptors, the low affinity P75 receptor and the Trk family of high affinity tyrosine kinase receptors. NGF preferentially binds TrkA, BDNF and NT4/5 bind TrkB, and NT-3 binds TrkC (and TrkA to a lesser extent).
BDNF分子の別称
BDNF,ANON2,BULN2,Abrineurin
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Tetramethylpyrazine Nitrone | Phase 3 Clinical | Jinan University | Amyotrophic Lateral Sclerosis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ischemic Stroke | 詳細 | |
| JS1-1-01 | JS1-1-01 | Phase 3 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Depression; Depressive Disorder; Depressive Disorder, Major | 詳細 |
| ACT-01 | ACT-01; OCS-05; BN-201; G-79 | Phase 2 Clinical | Promius Pharma | Keratosis, Actinic; Optic Neuritis | 詳細 |
| Aldifen | MP101; NSC-1532; MP-101 | Phase 2 Clinical | Mitochon Pharmaceuticals | Amyotrophic Lateral Sclerosis; Huntington Disease; Multiple Sclerosis | 詳細 |
| ALTO-100 | ALTO-100 | Phase 2 Clinical | Alto Neuroscience Inc | Bipolar I Disorder; Bipolar II Disorder; Depressive Disorder, Major; Stress Disorders, Post-Traumatic | 詳細 |
| AC-102 | AC-102 | Phase 2 Clinical | AudioCure Pharma GmbH | Hearing Loss, Sensorineural; Hearing Loss, Sudden; Tinnitus | 詳細 |
| Laquinimod Sodium | TV-5600; ABR-215062; SAIK-MS | Phase 1 Clinical | Active Biotech Ab | Arthritis; Crohn Disease; Eye Diseases; Huntington Disease; Lupus Nephritis; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Uveitis | 詳細 |
| AAV2-BDNF gene therapy (University Of California San Diego) | Phase 1 Clinical | University Of California San Diego | Alzheimer Disease; Cognitive Dysfunction | 詳細 |
- 詳細
- 製品リスト
- 治験薬に関する情報